Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated to reflect a new version, v2.16.8, of the HHS Vulnerability Disclosure, replacing the previous version v2.16.6.SummaryDifference0.2%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check20 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference1%
- Check27 days agoChange DetectedThe page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check34 days agoNo Change Detected
- Check41 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1.0%
- Check55 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.